Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

CC-486 (oral azacitidine) is an epigenetic modifier in development for patients with myelodysplastic syndromes and acute myeloid leukemia. In part 1 of this two-part study, a 7-day CC-486 dosing schedule showed clinical activity, was generally well tolerated, and reduced DNA methylation. Extending d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Laille, Eric, Shi, Tao, Garcia-Manero, Guillermo, Cogle, Christopher R., Gore, Steven D., Hetzer, Joel, Kumar, Keshava, Skikne, Barry, MacBeth, Kyle J.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4546409/
https://ncbi.nlm.nih.gov/pubmed/26296092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0135520
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars